This article is more than 5 years old. Information may no longer be current.

FDA approves Bausch + Lomb's Lumify for treatment of eye redness

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA approved Bausch + Lomb’s Lumify as the first over-the-counter eye drop developed with low-dose brimonidine tartrate for the treatment of ocular redness.

Brimonidine was first approved by the FDA in 1996 for the reduction of IOP in glaucoma patients, according to a press release from Valeant Pharmaceuticals.

“Lumify is the first and only OTC eye drop with low-dose brimonidine, which has been clinically proven to be safe and effective since its initial approval as a prescription medication in 1996,” Joseph C. Papa, chairman and CEO of Valeant, said in the release.

Lumify (brimonidine tartrate ophthalmic solution 0.025%) is expected to be available in the second quarter of 2018.

Frequent use of non-selective redness-relieving eye drops that constrict blood vessels in the eye may cause patients to develop a tolerance or loss of effectiveness. Low-dose brimonidine can lower this risk by selectively constricting veins in the eyes and increasing the availability of oxygen to the surrounding eye tissues, the release said.